EUVIMEDEUVIMED entdecken
Multizentrische Studie

Definitive Stereotactic Body Radiation Therapy in Early-Stage Solitary Hepatocellular Carcinoma: An Australian Multi-Institutional Review of Outcomes

H Y-H Liu, Y-Y D Lee, S Sridharan, W Wang, R Khor, J Chu, A Oar, E S Choong, H Le, M Shanker, A Wigg, K Stuart und 1 weitere

Clinical Oncology · 2023-12 · 35 (12) · 787-793

DOI: 10.1016/j.clon.2023.08.012 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Oncology, 2023-12. Verfasst von H Y-H Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Services, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia; Faculty of Medicine, University of Queensland, St. …. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Radiosurgery. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Standard curative options for early-stage, solitary hepatocellular carcinoma (HCC) are often unsuitable due to liver dysfunction, comorbidities and/or tumour location. Stereotactic body radiation therapy (SBRT) has shown high rates of local control in HCC; however, limited data exist in the treatment-naïve, curative-intent setting. We report the outcomes of patients with solitary early-stage HCC treated with SBRT as first-line curative-intent therapy. MATERIALS AND METHODS: A multi-institutional retrospective study of treatment-naïve patients with Barcelona Clinic Liver Cancer stage 0/A, solitary ≤5 cm HCC, Child-Pugh score (CPS) A liver function who underwent SBRT between 2010 and 2019 as definitive therapy. The primary end point was freedom from local progression. Secondary end points were progression-free survival, overall survival, rate of treatment-related clinical toxicities and change in CPS >1. RESULTS: In total, 68 patients were evaluated, with a median follow-up of 20 months (range 3-58). The median age was 68 years (range 50-86); 54 (79%) were men, 62 (91%) had cirrhosis and 50 (74%) were Eastern Cooperative Oncology Group 0. The median HCC diameter was 2.5 cm (range 1.3-5) and the median prescription biologically effective dose with a tumour a/b ratio of 10 Gy (BED10) was 93 Gy (interquartile range 72-100 Gy). Two-year freedom from local progression, progression-free survival and overall survival were 94.3% (95% confidence interval 86.6-100%), 59.5% (95% confidence interval 46.3-76.4%) and 88% (95% confidence interval 79.2-97.6%), respectively. Nine patients (13.2%) experienced grade ≥2 treatment-related clinical toxicities. A rise >1 in CPS was observed in six cirrhotic patients (9.6%). CONCLUSION: SBRT is an effective and well-tolerated option to consider in patients with solitary, early-stage HCC. Prospective, randomised comparative studies are warranted to further refine its role as a first-line curative-intent therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsRadiosurgeryMaleHumansMiddle AgedAgedAged, 80 and overFemaleRetrospective StudiesProspective StudiesTreatment OutcomeAustralia

Stichwörter der Autor:innen

Curative intentHepatocellular carcinomaStereotactic ablative radiation therapyStereotactic body radiation therapy

Autor:innen und Institutionen

  • Department of Cancer Services, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia; Faculty of Medicine, University of Queensland, St. Lucia, Queensland, Australia. Electronic address: howard.liu@health.ql…
  • Department of Cancer Services, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia; Faculty of Medicine, University of Queensland, St. Lucia, Queensland, Australia.
  • Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, New South Wales, Australia.
  • Department of Radiation Oncology, The Crown Princess Mary Cancer Centre, Westmead, New South Wales, Australia; Department of Radiation Oncology, Nepean Cancer Care Centre, Kingswood, New South Wales, Australia.
  • Department of Radiation Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia.
  • Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Zitieren

APA

Liu, H. Y., Lee, Y. D., Sridharan, S., Wang, W., Khor, R., Chu, J., Oar, A., Choong, E. S., Le, H., Shanker, M., Wigg, A., Stuart, K., & Pryor, D. (2023). Definitive Stereotactic Body Radiation Therapy in Early-Stage Solitary Hepatocellular Carcinoma: An Australian Multi-Institutional Review of Outcomes. Clinical Oncology, 35(12), 787-793. https://doi.org/10.1016/j.clon.2023.08.012

Vancouver

Liu HY, Lee YD, Sridharan S, Wang W, Khor R, Chu J, et al. Definitive Stereotactic Body Radiation Therapy in Early-Stage Solitary Hepatocellular Carcinoma: An Australian Multi-Institutional Review of Outcomes. Clinical Oncology. 2023;35(12):787-793. doi:10.1016/j.clon.2023.08.012

BibTeX
@article{Liu2023,
  author = {Liu, H Y-H and Lee, Y-Y D and Sridharan, S and Wang, W and Khor, R and Chu, J and Oar, A and Choong, E S and Le, H and Shanker, M and Wigg, A and Stuart, K and Pryor, D},
  title = {Definitive Stereotactic Body Radiation Therapy in Early-Stage Solitary Hepatocellular Carcinoma: An Australian Multi-Institutional Review of Outcomes},
  journal = {Clinical Oncology},
  year = {2023},
  volume = {35},
  number = {12},
  pages = {787--793},
  doi = {10.1016/j.clon.2023.08.012}
}
Kostenlos starten →